GenCore version 5.1.4_p5_4578

OM protein - protein search, using sw model

Run on: March 24, 2003, 16:05:20 ; Search time 42 Seconds
(without alignments)
828.057 Million cell updates/sec

Title: US-09-988-971-2
Perfect score: 261
Sequence: 1 MGSLPSRRKSLPSPSLSSSV.....RESLSFYISLNDEAVSLDDA 261

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 908470 seqs, 133250620 residues

Word size : 0

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 100 summaries

Database : A_Geneseq_101002:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	261	100.0	261	23	AAO15457	Human modulator of
2	178	68.2	210	23	AAO15458	Mouse modulator of
3	173	66.3	261	23	AAU91308	Human protein NOV1
4	155	59.4	248	21	AAB42993	Human ORFX ORF2757
5	63	24.1	70	22	ABG05994	Novel human diagno
6	37	14.2	259	23	AAO15456	Mouse modulator of
7	34	13.0	395	22	AAU31598	Novel human secret
8	31	11.9	31	22	ABB30170	Peptide #2821 enco
9	31	11.9	31	22	ABB35338	Peptide #2844 enco
10	31	11.9	31	22	ABB20778	Protein #2777 enco
11	31	11.9	31	22	AAM56170	Human brain expres
12	31	11.9	31	22	AAM68542	Human bone marrow
13	31	11.9	31	22	AAM16347	Peptide #2781 enco
14	31	11.9	31	22	AAM28843	Peptide #2880 enco
15	31	11.9	31	22	AAM04086	Peptide #2768 enco
16	31	11.9	31	23	ABG38121	Human peptide enco
17	9	3.4	384	22	AAE02493	Human CON103 G pro
18	9	3.4	384	23	AAU74911	Amino acid sequenc
19	9	3.4	423	20	AAW88460	Human 7-transmembr
20	9	3.4	423	22	AAG78785	Human opioid-type
21	9	3.4	423	22	AAU04365	Human G-protein co
22	9	3.4	455	21	AAY94339	Human cell surface
23	9	3.4	552	22	ABB57777	Drosophila melanog
24	9	3.4	552	22	ABB66713	Drosophila melanog
25	8	3.1	55	22	AAM25233	Human protein sequ
26	8	3.1	84	21	AAG12482	Zea mays protein f
27	8	3.1	90	22	AAM90260	Human immune/haema
28	8	3.1	106	17	AAW03989	SH2 domain from hu
29	8	3.1	106	17	AAW02127	Human Grb2 SH2 dom
30	8	3.1	110	21	AAG12481	Zea mays protein f
31	8	3.1	167	22	AAM84060	Human immune/haema
32	8	3.1	217	16	AAR85918	Human GRB-2. Homo
33	8	3.1	217	18	AAW18063	Growth factor rece
34	8	3.1	217	18	AAW14004	Human GRB2. Homo
35	8	3.1	217	19	AAW42070	Growth factor rece
36	8	3.1	217	23	ABB57107	Mouse ischaemic co
37	8	3.1	242	22	ABG06869	Novel human diagno
38	8	3.1	258	22	ABB66027	Drosophila melanog
39	8	3.1	315	22	AAU31072	Novel human secret
40	8	3.1	317	13	AAR26061	Growth Factor Rece
41	8	3.1	402	22	AAB48967	Human PI3 kinase p
42	8	3.1	454	17	AAR90571	pp60PIK. Mus musc
43	8	3.1	505	22	AAB99332	Human tyrosine kin
44	8	3.1	767	21	AAG41930	Arabidopsis thalia
45	8	3.1	822	21	AAG41929	Arabidopsis thalia
46	8	3.1	3048	22	ABG25791	Novel human diagno
47	7	2.7	10	22	AAB66758	Beta6 cytoplasmic
48	7	2.7	14	23	ABG34896	Human G-protein co
49	7	2.7	22	22	AAB66752	Beta6 cytoplasmic
50	7	2.7	24	20	AAY22150	Peptide used for F
51	7	2.7	50	21	AAB63049	Human secreted pro
52	7	2.7	50	22	AAU46391	Propionibacterium
53	7	2.7	52	22	AAB66764	Beta6 subunit cyto
54	7	2.7	55	22	AAU57731	Propionibacterium
55	7	2.7	58	19	AAW65883	Cytoplasmic domain
56	7	2.7	58	20	AAY43094	Human integrin bet
57	7	2.7	58	23	ABP08174	Human ORFX protein
58	7	2.7	64	23	ABP10647	Human ORFX protein
59	7	2.7	65	20	AAW88611	Secreted protein e
60	7	2.7	65	22	ABB50378	Human secreted pro
61	7	2.7	67	22	AAU39974	Propionibacterium
62	7	2.7	69	22	AAU60743	Propionibacterium
63	7	2.7	77	22	ABB30538	Peptide #3189 enco
64	7	2.7	77	22	ABB35702	Peptide #3208 enco
65	7	2.7	77	22	ABB21131	Protein #3130 enco
66	7	2.7	77	22	AAM56513	Human brain expres
67	7	2.7	77	22	AAM68894	Human bone marrow
68	7	2.7	77	22	AAM16718	Peptide #3152 enco
69	7	2.7	77	22	AAM29205	Peptide #3242 enco
70	7	2.7	77	22	AAM04433	Peptide #3115 enco
71	7	2.7	77	23	ABG38475	Human peptide enco
72	7	2.7	78	23	ABG34869	Human G-protein co
73	7	2.7	78	23	ABP35416	Human ORF4389 prot
74	7	2.7	80	22	AAU45754	Propionibacterium
75	7	2.7	82	20	AAY13165	Human secreted pro
76	7	2.7	90	23	ABP02511	Human ORFX protein
77	7	2.7	91	22	AAE03500	Human gene 19 enco
78	7	2.7	91	23	ABG63342	Human albumin fusi
79	7	2.7	95	19	AAY21419	Human high mobilit
80	7	2.7	96	23	ABB91360	Herbicidally activ
81	7	2.7	99	22	ABG17416	Novel human diagno
82	7	2.7	100	22	ABG21294	Novel human diagno
83	7	2.7	104	18	AAY11178	S. pneumoniae 30S

84	7	2.7	108	21	AAB41391	Human ORFX ORF1155
85	7	2.7	110	22	AAM06474	Human foetal prote
86	7	2.7	110	22	AAM06754	Human foetal prote
87	7	2.7	115	23	ABB47453	Listeria monocytog
88	7	2.7	116	22	AAM06621	Human foetal prote
89	7	2.7	125	22	AAO02627	Human polypeptide
90	7	2.7	131	22	AAM90046	Human immune/haema
91	7	2.7	144	22	AAU41069	Propionibacterium
92	7	2.7	161	22	AAU39509	Propionibacterium
93	7	2.7	163	22	AAU27502	Human G-Protein Co
94	7	2.7	168	22	AAU58491	Propionibacterium
95	7	2.7	169	23	ABB81561	Human N-acetylgluc
96	7	2.7	172	22	AAU65751	Propionibacterium
97	7	2.7	177	20	AAY37602	Protein which is s
98	7	2.7	189	23	AAU12122	Arabidopsis hr3 pr
99	7	2.7	201	23	ABB06200	Human central cann
100	7	2.7	219	23	ABB53497	Lactococcus lactis

ALIGNMENTS

RESULT 1
AAO15457
ID AAO15457 standard; Protein; 261 AA.
XX
AC AAO15457;
XX
DT 03-OCT-2002 (first entry)
XX
DE Human modulator of antigen receptor signalling (MARS) protein.
XX
KW Human; gene therapy; modulator of antigen receptor signalling; MARS;
KW tumour suppressor gene; Scr-like adaptor protein; SLAP;
KW myeloid malignancy; acute myelogenous leukaemia; autoimmune disorder;
KW immunosuppression; myeloproliferative disorder; breast cancer.
XX
OS Homo sapiens.
XX
PN WO200242452-A2.
XX
PD 30-MAY-2002.
XX
PF 26-NOV-2001; 2001WO-CA01662.
XX
PR 27-NOV-2000; 2000CA-2324663.
XX
PA (HOSP-) HOSPITAL FOR SICK CHILDREN.
XX
PI Mcglade JC, Loreto MP;
XX
DR WPI; 2002-566564/60.
DR N-PSDB; AAL44089.
XX
PT New isolated modulator of antigen receptor signaling protein or its
PT fragment, useful for treating malignant disorders such as myeloid
PT malignancies, autoimmune disorders and myeloproliferative disorders -
XX
PS Claim 7; Fig 9A; 110pp; English.
XX
CC The invention comprises the amino acid and coding sequences of modulator
CC of antigen receptor signalling (MARS) proteins. The MARS protein is a
CC putative tumour suppressor gene and exhibits structural and sequence
CC similarity to the Scr-like adaptor protein (SLAP). The MARS DNA and
CC protein sequences of the invention are useful for the treatment of
CC myeloid malignancies (e.g. acute myelogenous leukaemia) autoimmune
CC disorders, immunosuppression, myeloproliferative disorders and
CC malignancies related to the de-regulation of tyrosine kinases (e.g.
CC breast cancer). The present amino acid sequence represents a human MARS
CC protein.
XX
SQ Sequence 261 AA;

Query Match 100.0%; Score 261; DB 23; Length 261;
Best Local Similarity 100.0%; Pred. No. 1.6e-224;
Matches 261; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      1 MGSLPSRRKSLPSPSLSSSVQGQGPVTMEAERSKATAVALGSFPAGGPAELSLRLGEPLT 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 MGSLPSRRKSLPSPSLSSSVQGQGPVTMEAERSKATAVALGSFPAGGPAELSLRLGEPLT 60

Qy     61 IVSEDGDWWTVLSEVSGREYNIPSVHVAKVSHGWLYEGLSREKAEELLLLPGNPGGAFLI 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 IVSEDGDWWTVLSEVSGREYNIPSVHVAKVSHGWLYEGLSREKAEELLLLPGNPGGAFLI 120

Qy    121 RESQTRRGSYSLSVRLSRPASWDRIRHYRIHCLDNGWLYISPRLTFPSLQALVDHYSELA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 RESQTRRGSYSLSVRLSRPASWDRIRHYRIHCLDNGWLYISPRLTFPSLQALVDHYSELA 180

Qy    181 DDICCLLKEPCVLQRAGPLPGKDIPLPVTVQRTPLNWKELDSSLLFSEAATGEESLLSEG 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 DDICCLLKEPCVLQRAGPLPGKDIPLPVTVQRTPLNWKELDSSLLFSEAATGEESLLSEG 240

Qy    241 LRESLSFYISLNDEAVSLDDA 261
          |||||||||||||||||||||
Db    241 LRESLSFYISLNDEAVSLDDA 261
```

RESULT 2
AAO15458
ID AAO15458 standard; Protein; 210 AA.
XX
AC AAO15458;
XX
DT 03-OCT-2002 (first entry)
XX
DE Mouse modulator of antigen receptor signalling short isoform protein.
XX
KW Mouse; gene therapy; modulator of antigen receptor signalling; MARS;
KW tumour suppressor gene; Scr-like adaptor protein; SLAP;
KW myeloid malignancy; acute myelogenous leukaemia; autoimmune disorder;
KW immunosuppression; myeloproliferative disorder; breast cancer.
XX
OS Mus sp.
XX
PN WO200242452-A2.
XX
PD 30-MAY-2002.
XX
PF 26-NOV-2001; 2001WO-CA01662.
XX
PR 27-NOV-2000; 2000CA-2324663.
XX
PA (HOSP-) HOSPITAL FOR SICK CHILDREN.
XX
PI Mcglade JC, Loreto MP;
XX
DR WPI; 2002-566564/60.
DR N-PSDB; AAL44090.
XX
PT New isolated modulator of antigen receptor signaling protein or its
PT fragment, useful for treating malignant disorders such as myeloid
PT malignancies, autoimmune disorders and myeloproliferative disorders -
XX
PS Claim 8; Page 78; 110pp; English.
XX
CC The invention comprises the amino acid and coding sequences of modulator
CC of antigen receptor signalling (MARS) proteins. The MARS protein is a
CC putative tumour suppressor gene and exhibits structural and sequence
CC similarity to the Scr-like adaptor protein (SLAP). The MARS DNA and
CC protein sequences of the invention are useful for the treatment of
CC myeloid malignancies (e.g. acute myelogenous leukaemia) autoimmune
CC disorders, immunosuppression, myeloproliferative disorders and
CC malignancies related to the de-regulation of tyrosine kinases (e.g.
CC breast cancer). The present amino acid sequence represents a mouse MARS
CC protein.

```
XX
SQ   Sequence   210 AA;

  Query Match             68.2%;  Score 178;  DB 23;  Length 210;
  Best Local Similarity   100.0%;  Pred. No. 1.3e-150;
  Matches  178;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MGSLPSRRKSLPSPSLSSSVQGQGPVTMEAERSKATAVALGSFPAGGPAELSLRLGEPLT 60
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1 MGSLPSRRKSLPSPSLSSSVQGQGPVTMEAERSKATAVALGSFPAGGPAELSLRLGEPLT 60

Qy      61 IVSEDGDWWTVLSEVSGREYNIPSVHVAKVSHGWLYEGLSREKAEELLLLPGNPGGAFLI 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      61 IVSEDGDWWTVLSEVSGREYNIPSVHVAKVSHGWLYEGLSREKAEELLLLPGNPGGAFLI 120

Qy     121 RESQTRRGSYSLSVRLSRPASWDRIRHYRIHCLDNGWLYISPRLTFPSLQALVDHYSE 178
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     121 RESQTRRGSYSLSVRLSRPASWDRIRHYRIHCLDNGWLYISPRLTFPSLQALVDHYSE 178


RESULT 3
AAU91308
ID   AAU91308 standard; Protein; 261 AA.
XX
AC   AAU91308;
XX
DT   18-JUN-2002  (first entry)
XX
DE   Human protein NOV13.
XX
KW   Human; NOVX; gene therapy; cardiomyopathy; atherosclerosis;
KW   cell signal processing disorder; metabolic pathway modulation disorder;
KW   diabetes; cancer; adenocarcinoma; lymphoma; prostate cancer;
KW   uterus cancer; immune response; graft-versus-host disease;
KW   acquired immunodeficiency syndrome; AIDS; asthma; Crohn's disease;
KW   hypertension; congenital heart defects; multiple sclerosis; inflammation;
KW   Albright hereditary osteodystrophy.
XX
OS   Homo sapiens.
XX
PN   WO200216599-A2.
XX
PD   28-FEB-2002.
XX
PF   27-AUG-2001; 2001WO-US26510.
XX
PR   25-AUG-2000; 2000US-228191P.
PR   08-FEB-2001; 2001US-267300P.
PR   20-FEB-2001; 2001US-269961P.
PR   20-MAR-2001; 2001US-277337P.
XX
PA   (CURA-) CURAGEN CORP.
PA   (CORT-) COR THERAPEUTICS INC.
XX
PI   Burgess CE,  Conley PB,  Grosse WM,  Hart M,  Kekuda R,  Shimkets RA;
PI   Spytek KA,  Szekeres ES,  Tomlinson JE,  Topper JN,  Yang R;
XX
DR   WPI; 2002-280937/32.
DR   N-PSDB; ABK61465.
XX
PT   New polypeptides for treating or preventing a  disorder associated with
PT   them, in humans, e.g. cardiomyopathy, atherosclerosis or cancers -
XX
PS   Claim 3; Page 98; 263pp; English.
XX
CC   The invention relates to an isolated polypeptide (NOVX) a mature
CC   form of NOVX, a NOVX variant (differing by no  more than 15%), the
CC   nucleotide encoding NOVX (or its complement, fragment or variant).
CC   NOVX is NOV1-14, 15a, 15b, 16a, and 16b. The NOVX polypeptide, nucleic
CC   acid encoding it and antibody against it, are useful for treating or
CC   preventing (e.g. by gene therapy) a NOVX-associated disorder in humans,
CC   e.g. cardiomyopathy, atherosclerosis, a disorder related to cell signal
CC   processing and metabolic pathway modulation, diabetes or cancers. The
CC   NOVX polypeptide and nucleic acids are also useful for determining the
CC   presence of predisposition to the diseases. The NOVX nucleic acid and
CC   polypeptide are especially useful in therapeutic or prophylactic
CC   applications for disorders associated with aberrant NOVX expression or
CC   activity, e.g. cancers (e.g. adenocarcinoma, lymphoma, prostate cancer or
CC   uterus cancer), immune response, graft-versus-host disease, acquired
CC   immunodeficiency syndrome (AIDS), asthma, Crohn's disease, hypertension,
CC   congenital heart defects, multiple sclerosis, inflammation or Albright
CC   hereditary osteodystrophy and many other diseases listed in the
CC   specification. The DNA encoding the protein is useful in gene therapy
CC   for treating the conditions. This is also useful in detection assays,
CC   chromosome mapping, tissue typing, diagnostic or prognostic assays, or
CC   for developing a powerful assay system for functional analysis of
CC   various human disorders, as well as in diagnostic applications. The
CC   present sequence represents a NOVX protein.
XX
SQ   Sequence   261 AA;

  Query Match             66.3%;  Score 173;  DB 23;  Length 261;
  Best Local Similarity   100.0%;  Pred. No. 4.5e-146;
  Matches  173;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      89 KVSHGWLYEGLSREKAEELLLLPGNPGGAFLIRESQTRRGSYSLSVRLSRPASWDRIRHY 148
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      89 KVSHGWLYEGLSREKAEELLLLPGNPGGAFLIRESQTRRGSYSLSVRLSRPASWDRIRHY 148

Qy     149 RIHCLDNGWLYISPRLTFPSLQALVDHYSELADDICCLLKEPCVLQRAGPLPGKDIPLPV 208
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     149 RIHCLDNGWLYISPRLTFPSLQALVDHYSELADDICCLLKEPCVLQRAGPLPGKDIPLPV 208

Qy     209 TVQRTPLNWKELDSSLLFSEAATGEESLLSEGLRESLSFYISLNDEAVSLDDA 261
           |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     209 TVQRTPLNWKELDSSLLFSEAATGEESLLSEGLRESLSFYISLNDEAVSLDDA 261


RESULT 4
AAB42993
ID   AAB42993 standard; Protein; 248 AA.
XX
AC   AAB42993;
XX
DT   08-FEB-2001  (first entry)
XX
DE   Human ORFX ORF2757 polypeptide sequence SEQ ID NO:5514.
XX
KW   Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
KW   vulnerary; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
KW   anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
KW   immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
KW   hypotensive; dermatological; immunosuppressive; antiinflammatory;
KW   antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
KW   antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
KW   neurodegenerative disorder; osteoarthritis; graft vs host disease;
KW   cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
KW   cholesterol ester storage; systemic lupus erythematosus; infection;
KW   severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
KW   allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
KW   bone damage; cartilage damage; antiinflammatory disease; coagulation;
KW   thrombosis; contraceptive.
XX
OS   Homo sapiens.
XX
PN   WO200058473-A2.
XX
PD   05-OCT-2000.
XX
PF   31-MAR-2000; 2000WO-US08621.
XX
PR   31-MAR-1999;   99US-0127607.
PR   02-APR-1999;   99US-0127636.
PR   05-APR-1999;   99US-0127728.
PR   30-MAR-2000; 2000US-0540763.
XX
```

```
PA   (CURA-) CURAGEN CORP.
XX
PI   Shimkets RA,  Leach M;
XX
DR   WPI; 2000-602362/57.
DR   N-PSDB; AAC77202.
XX
PT   Novel nucleic acids and peptides derived from open reading frame X,
PT   useful for treating e.g. cancers, proliferative disorders,
PT   neurodegenerative disorders and cardiovascular disease -
XX
PS   Claim 11; Page 4693-4694; 5507pp; English.
XX
CC   AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
CC   which represent the human ORFX open reading frames 1 to 3161. The ORFX
CC   sequences have activities such as: cytostatic; hepatotropic; vulnerary;
CC   antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
CC   osteopathic; anticonvulsant; antiarthritic; immunosuppressant;
CC   immunostimulant; cardiant; thrombolytic; coagulant; vasotropic;
CC   antidiabetic; hypotensive; dermatological; immunosuppressive;
CC   antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;
CC   antithyroid; and antianaemic. The sequences can be used for determining
CC   the presence of or predisposition to, or preventing or treating
CC   pathological conditions associated with an ORFX-associated disorder. The
CC   nucleic acids can be used to express ORFX proteins in gene therapy
CC   vectors. The proteins and nucleic acids may be used to treat cancers,
CC   proliferative disorders, neurodegenerative disorders, osteoarthritis,
CC   graft vs host disease, cardiovascular disease, diabetes mellitus,
CC   hypertension, hypothyroidism, cholesterol ester storage, systemic lupus
CC   erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,
CC   bacterial or fungal infection, malaria, autoimmune disorders, asthma,
CC   allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,
CC   nocturnal haemoglobinuria, antiinflammatory disease; to enhance
CC   coagulation; to inhibit thrombosis; and as a contraceptive.
XX
SQ   Sequence   248 AA;

  Query Match            59.4%;  Score 155;  DB 21;  Length 248;
  Best Local Similarity  100.0%;  Pred. No. 4.9e-130;
  Matches  155;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     107 LLLLPGNPGGAFLIRESQTRRGSYSLSVRLSRPASWDRIRHYRIHCLDNGWLYISPRLTF 166
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      94 LLLLPGNPGGAFLIRESQTRRGSYSLSVRLSRPASWDRIRHYRIHCLDNGWLYISPRLTF 153

Qy     167 PSLQALVDHYSELADDICCLLKEPCVLQRAGPLPGKDIPLPVTVQRTPLNWKELDSSLLF 226
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     154 PSLQALVDHYSELADDICCLLKEPCVLQRAGPLPGKDIPLPVTVQRTPLNWKELDSSLLF 213

Qy     227 SEAATGEESLLSEGLRESLSFYISLNDEAVSLDDA 261
           |||||||||||||||||||||||||||||||||||
Db     214 SEAATGEESLLSEGLRESLSFYISLNDEAVSLDDA 248


RESULT 5
ABG05994
ID   ABG05994 standard; Protein; 70 AA.
XX
AC   ABG05994;
XX
DT   13-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #5985.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS70181.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 20; SEQ ID No 36353; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   70 AA;

  Query Match            24.1%;  Score 63;  DB 22;  Length 70;
  Best Local Similarity  100.0%;  Pred. No. 1.8e-48;
  Matches   63;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      65 DGDWWTVLSEVSGREYNIPSVHVAKVSHGWLYEGLSREKAEELLLLPGNPGGAFLIRESQ 124
           |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       8 DGDWWTVLSEVSGREYNIPSVHVAKVSHGWLYEGLSREKAEELLLLPGNPGGAFLIRESQ 67

Qy     125 TRR 127
           |||
Db      68 TRR 70


RESULT 6
AAO15456
ID   AAO15456 standard; Protein; 259 AA.
XX
AC   AAO15456;
XX
DT   03-OCT-2002  (first entry)
XX
DE   Mouse modulator of antigen receptor signalling (MARS) protein.
XX
KW   Mouse; gene therapy; modulator of antigen receptor signalling; MARS;
KW   tumour suppressor gene; Scr-like adaptor protein; SLAP;
KW   myeloid malignancy; acute myelogenous leukaemia; autoimmune disorder;
KW   immunosuppression; myeloproliferative disorder; breast cancer.
XX
OS   Mus sp.
XX
```

PN WO200242452-A2.
XX
PD 30-MAY-2002.
XX
PF 26-NOV-2001; 2001WO-CA01662.
XX
PR 27-NOV-2000; 2000CA-2324663.
XX
PA (HOSP-) HOSPITAL FOR SICK CHILDREN.
XX
PI Mcglade JC, Loreto MP;
XX
DR WPI; 2002-566564/60.
DR N-PSDB; AAL44087.
XX
PT New isolated modulator of antigen receptor signaling protein or its
PT fragment, useful for treating malignant disorders such as myeloid
PT malignancies, autoimmune disorders and myeloproliferative disorders -
XX
PS Claim 7; Fig 1A; 110pp; English.
XX
CC The invention comprises the amino acid and coding sequences of modulator
CC of antigen receptor signalling (MARS) proteins. The MARS protein is a
CC putative tumour suppressor gene and exhibits structural and sequence
CC similarity to the Scr-like adaptor protein (SLAP). The MARS DNA and
CC protein sequences of the invention are useful for the treatment of
CC myeloid malignancies (e.g. acute myelogenous leukaemia) autoimmune
CC disorders, immunosuppression, myeloproliferative disorders and
CC malignancies related to the de-regulation of tyrosine kinases (e.g.
CC breast cancer). The present amino acid sequence represents a mouse MARS
CC protein.
XX
SQ Sequence 259 AA;

Query Match 14.2%; Score 37; DB 23; Length 259;
Best Local Similarity 100.0%; Pred. No. 7.9e-25;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 92 HGWLYEGLSREKAEELLLLPGNPGGAFLIRESQTRRG 128
||||||||||||||||||||||||||||||||||||||
Db 91 HGWLYEGLSREKAEELLLLPGNPGGAFLIRESQTRRG 127

RESULT 7
AAU31598
ID AAU31598 standard; Protein; 395 AA.
XX
AC AAU31598;
XX
DT 18-DEC-2001 (first entry)
XX
DE Novel human secreted protein #2089.
XX
KW Human; vaccination; gene therapy; nutritional supplement;
KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
XX
OS Homo sapiens.
XX
PN WO200179449-A2.
XX
PD 25-OCT-2001.
XX
PF 16-APR-2001; 2001WO-US08656.
XX
PR 18-APR-2000; 2000US-0552929.
PR 26-JAN-2001; 2001US-0770160.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-611725/70.
XX
PT Nucleic acids encoding a range of human polypeptides, useful in genetic
PT vaccination, testing and therapy -
XX
PS Claim 20; Page 464-465; 765pp; English.
XX
CC The invention relates to novel human secreted polypeptides. The
CC polypeptides and antibodies to the polypeptides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of polypeptide. The polypeptides are also useful for
CC identifying agents (agonists and antagonists) that bind to them. Cells
CC expressing the proteins are useful for identifying a therapeutic agent
CC for use in treatment of a pathology related to aberrant expression or
CC physiological interactions of the polypeptide. Vectors comprising
CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation; to regulate haematopoiesis; and in
CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
CC immune suppression and/or stimulation; as anti-inflammatory agents; and
CC in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
CC sequences of novel human secreted proteins of the invention.
XX
SQ Sequence 395 AA;

Query Match 13.0%; Score 34; DB 22; Length 395;
Best Local Similarity 100.0%; Pred. No. 5.3e-22;
Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 31 ERSKATAVALGSFPAGGPAELSLRLGEPLTIVSE 64
||||||||||||||||||||||||||||||||
Db 362 ERSKATAVALGSFPAGGPAELSLRLGEPLTIVSE 395

RESULT 8
ABB30170
ID ABB30170 standard; Peptide; 31 AA.
XX
AC ABB30170;
XX
DT 01-FEB-2002 (first entry)
XX
DE Peptide #2821 encoded by breast cell single exon nucleic acid probe.
XX
KW Human; microarray; single exon probe; gene expression; breast;
KW disease; cancer.
XX
OS Homo sapiens.
XX
PN WO200157271-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US00662.
XX
PR 04-FEB-2000; 2000US-0180312.
PR 26-MAY-2000; 2000US-0207456.
PR 30-JUN-2000; 2000US-0608408.
PR 03-AUG-2000; 2000US-0632366.
PR 21-SEP-2000; 2000US-0234687.
PR 27-SEP-2000; 2000US-0236359.
PR 04-OCT-2000; 2000GB-0024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-496933/54.
XX
PT New spatially-addressable set of single exon nucleic acid probes,
PT useful for measuring gene expression in sample derived from human
PT breast, comprises number of single exon nucleic acid probes -

```
XX
PS   Claim 27; SEQ ID NO 13138; 327pp + sequence listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting
CC   the probes with a collection of detectably labelled nucleic acids
CC   derived from mRNA of human breast, and then measuring the label
CC   bound to each probe of the microarray. The probes are useful for
CC   verifying the expression of regions of genomic DNA predicted to
CC   encode proteins. They are useful for gene discovery, and for
CC   determining predisposition and/or prognosing breast disease. Gene
CC   expression analysis is useful for assessing the toxicity of chemical
CC   agents on cells. The microarray of this invention presents a far greater
CC   diversity of probes for measuring gene expression, with far less bias
CC   than expressed sequence tag microarrays. The method is suitable for
CC   rapid production of functional information from genomic sequence. The
CC   present sequence is a peptide encoded by a single exon nucleic acid
CC   probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   31 AA;

  Query Match             11.9%;  Score 31;  DB 22;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 9
ABB35338
ID   ABB35338 standard; Peptide; 31 AA.
XX
AC   ABB35338;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #2844 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00669.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human fetal liver -
XX
PS   Claim 27; SEQ ID NO 27973; 639pp + sequence listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for
CC   measuring human gene expression in a sample derived from human foetal
CC   liver. The single exon nucleic acid probes may be used for predicting,
CC   measuring and displaying gene expression in samples derived from human
CC   fetal liver. The present sequence is a peptide encoded by a single exon
CC   nucleic acid probe of the invention.
CC   Note: The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   31 AA;

  Query Match             11.9%;  Score 31;  DB 22;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 10
ABB20778
ID   ABB20778 standard; Protein; 31 AA.
XX
AC   ABB20778;
XX
DT   23-JAN-2002  (first entry)
XX
DE   Protein #2777 encoded by probe for measuring heart cell gene expression.
XX
KW   Human; gene expression; heart; microarray; vascular system;
KW   cardiovascular disease; hypertension; cardiac arrhythmia;
KW   congenital heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157274-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00666.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488899/53.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   hearts -
XX
PS   Claim 15; SEQ ID No 22548; 530pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes for
CC   measuring human gene expression in a sample derived from human heart (see
CC   ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC   probe. The probes may be used for predicting, measuring and displaying
CC   gene expression in samples derived from the human heart via microarrays.
CC   By measuring gene expression, the probes are useful for predicting,
CC   diagnosing, grading, staging, monitoring and prognosing diseases of the
CC   human heart and vascular system e.g. cardiovascular disease,
CC   hypertension, cardiac arrhythmias and congenital heart disease.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
```

```
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   31 AA;

  Query Match            11.9%;  Score 31;  DB 22;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 11
AAM56170
ID   AAM56170 standard; Protein; 31 AA.
XX
AC   AAM56170;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 28275.
XX
KW   Human; brain expressed exon; gene expression analysis; probe;
KW   microarray; Alzheimer's disease; multiple sclerosis; schizophrenia;
KW   epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00667.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains -
XX
PS   Example 4; SEQ ID NO: 28275; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention.
XX
SQ   Sequence   31 AA;

  Query Match            11.9%;  Score 31;  DB 22;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 12
AAM68542
ID   AAM68542 standard; Protein; 31 AA.
XX
AC   AAM68542;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human bone marrow expressed probe encoded protein SEQ ID NO: 28848.
XX
KW   Human; bone marrow expressed exon; gene expression analysis; probe;
KW   microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS   Homo sapiens.
XX
PN   WO200157276-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00668.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488900/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human bone marrow -
XX
PS   Example 4; SEQ ID NO: 28848; 658pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention.
XX
SQ   Sequence   31 AA;

  Query Match            11.9%;  Score 31;  DB 22;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 13
AAM16347
ID   AAM16347 standard; Protein; 31 AA.
XX
AC   AAM16347;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #2781 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
```

```
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00670.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human cervical epithelial cells -
XX
PS   Claim 27; SEQ ID No 21173; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   31 AA;

  Query Match             11.9%;  Score 31;  DB 22;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 14
AAM28843
ID   AAM28843 standard; Protein; 31 AA.
XX
AC   AAM28843;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #2880 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US00663.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for
PT   analyzing gene expression in human placenta -
XX
PS   Claim 27; SEQ ID No 29112; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders.
XX
SQ   Sequence   31 AA;

  Query Match             11.9%;  Score 31;  DB 22;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 15
AAM04086
ID   AAM04086 standard; Protein; 31 AA.
XX
AC   AAM04086;
XX
DT   09-OCT-2001  (first entry)
XX
DE   Peptide #2768 encoded by probe for measuring breast gene expression.
XX
KW   Probe; human; breast disease; breast cancer; development disorder;
KW   inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS   Homo sapiens.
XX
PN   WO200157270-A2.
XX
PD   09-AUG-2001.
XX
PF   29-JAN-2001; 2001WO-US00661.
XX
PR   04-FEB-2000; 2000US-0180312.
PR   26-MAY-2000; 2000US-0207456.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-0234687.
PR   27-SEP-2000; 2000US-0236359.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-476286/51.
XX
PT   Novel single exon nucleic acid probe used to measuring gene expression
PT   in a human breast -
XX
PS   Claim 27; SEQ ID No 12826; 322pp; English.
XX
```

```
CC   The present invention relates to novel single exon nucleic acid probes
CC   (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for measuring human gene expression in
CC   a human breast sample, where the probe hybridises at high stringency to a
CC   nucleic acid expressed in the human breast. The probes are useful for
CC   predicting, diagnosing, grading, staging, monitoring and prognosing
CC   diseases of the human breast, particularly those diseases with polygenic
CC   aetiology. The diseases include: breast cancer, disorders of development,
CC   inflammatory diseases of the breast, fibrocystic changes, proliferative
CC   breast disease and non-carcinoma tumours.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   31 AA;

  Query Match             11.9%;  Score 31;  DB 22;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 16
ABG38121
ID   ABG38121 standard; Peptide; 31 AA.
XX
AC   ABG38121;
XX
DT   19-AUG-2002  (first entry)
XX
DE   Human peptide encoded by genome-derived single exon probe SEQ ID 27786.
XX
KW   Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW   chronic obstructive pulmonary disease; interstitial lung disease;
KW   familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW   tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW   Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW   pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW   pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW   primary ciliary dyskinesis; pulmonary hypertension;
KW   hyaline membrane disease.
XX
OS   Homo sapiens.
XX
PN   WO200186003-A2.
XX
PD   15-NOV-2001.
XX
PF   30-JAN-2001; 2001WO-US00665.
XX
PR   04-FEB-2000; 2000US-180312P.
PR   26-MAY-2000; 2000US-207456P.
PR   30-JUN-2000; 2000US-0608408.
PR   03-AUG-2000; 2000US-0632366.
PR   21-SEP-2000; 2000US-234687P.
PR   27-SEP-2000; 2000US-236359P.
PR   04-OCT-2000; 2000GB-0024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2002-114183/15.
XX
PT   Spatially-addressable set of single exon nucleic acid probes, used to
PT   measure gene expression in human lung samples -
XX
PS   Claim 27; SEQ ID No 27786; 634pp; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human lung comprising single exon nucleic acid probes having one of
CC   12614 nucleic acid sequences mentioned in the specification, or their
CC   complements or the 12387 open reading frames derived from the 12614
CC   probes. Also included are a microarray comprising the novel set of
CC   probes; the novel set of probes which hybridise at high stringency to a
CC   nucleic acid expressed in the human lung; measuring gene expression in a
CC   sample derived from human lung, comprising (a) contacting the array with
CC   a collection of detectably labeled nucleic acids derived from human lung
CC   mRNA, and (b) measuring the label detectably bound to each probe of
CC   the array; identifying exons in a eukaryotic genome, comprising
CC   (a) algorithmically predicting at least one exon from genomic sequences
CC   of the eukaryote; and (b) detecting specific hybridisation of detectably
CC   labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC   having a fragment identical to the predicted exon, the probe is included
CC   in the above mentioned microarray; assigning exons to a single gene,
CC   comprising (a) identifying exons from genomic sequence by the method
CC   above and (b) measuring the expression of each of the exons in several
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene
CC   expression analysis, and for identifying exons in a gene, particularly
CC   using human lung derived mRNA and for the study of lung diseases
CC   such as asthma, lung cancer, chronic obstructive pulmonary disease
CC   (COPD), interstitial lung disease (ILD), familial idiopathic pulmonary
CC   fibrosis, neurofibromatosis, tuberous sclerosis, Gaucher's disease,
CC   Niemann-Pick disease, Hermansky-Pudlak syndrome, sarcoidosis, pulmonary
CC   haemosiderosis, pulmonary histiocytosis, lymphangioleiomyomtosis,
CC   pulmonary alveolar proteinosis, Karagener syndrome, fibrocystic
CC   pulmonary dysplasia, primary ciliary dyskinesis, pulmonary hypertension
CC   and hyaline membrane disease. The present sequence is a peptide/protein
CC   encoded by a single exon probe of the invention.
CC   Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic
CC   format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   31 AA;

  Query Match             11.9%;  Score 31;  DB 23;  Length 31;
  Best Local Similarity   100.0%;  Pred. No. 3e-20;
  Matches   31;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    191 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 221
          |||||||||||||||||||||||||||||||
Db      1 CVLQRAGPLPGKDIPLPVTVQRTPLNWKELD 31


RESULT 17
AAE02493
ID   AAE02493 standard; Protein; 384 AA.
XX
AC   AAE02493;
XX
DT   10-AUG-2001  (first entry)
XX
DE   Human CON103 G protein-coupled receptor protein.
XX
KW   Human; G protein-coupled receptor; GPCR; CON103 protein; schizophrenia;
KW   neuroleptic; nootropic; neuroprotective; bipolar disease; psychotropic;
KW   neurological disorder; psychiatric disease; neurosis; anxiety; neuritis;
KW   attention deficit hyperactivity disorder; neurasthenia; senile dementia;
KW   affective disorder; neuropathy; Alzheimer's disease; Parkinson's disease;
KW   depression; migraine; genetic screening; chromosome 2.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Domain          54..77
FT                   /label= Transmembrane_domain_(1TM)
```

```
FT   Domain          78..88
FT                   /label= Intracellular_domain
FT                   /note= "First IC loop"
FT   Domain          89..108
FT                   /label= Transmembrane_domain_(2TM)
FT   Domain          109..133
FT                   /label= Extracellular_domain
FT                   /note= "First EC loop"
FT   Domain          134..149
FT                   /label= Transmembrane_domain_(3TM)
FT   Domain          150..166
FT                   /label= Intracellular_domain
FT                   /note= "Second IC loop"
FT   Domain          167..188
FT                   /label= Transmembrane_domain_(4TM)
FT   Domain          189..215
FT                   /label= Extracellular_domain
FT                   /note= "Second EC loop"
FT   Domain          216..240
FT                   /label= Transmembrane_domain_(5TM)
FT   Domain          241..257
FT                   /label= Intracellular_domain
FT                   /note= "Third IC loop"
FT   Domain          258..283
FT                   /label= Transmembrane_domain_(6TM)
FT   Domain          284..300
FT                   /label= Extracellular_domain
FT                   /note= "Third EC loop"
FT   Domain          301..320
FT                   /label= Transmembrane_domain_(7TM)
XX
PN   WO200131014-A2.
XX
PD   03-MAY-2001.
XX
PF   27-OCT-2000; 2000WO-US29601.
XX
PR   27-OCT-1999;   99US-0427653.
PR   27-OCT-1999;   99US-0427859.
PR   27-OCT-1999;   99US-0428020.
PR   27-OCT-1999;   99US-0428114.
PR   28-OCT-1999;   99US-0429517.
PR   28-OCT-1999;   99US-0429555.
PR   28-OCT-1999;   99US-0429676.
PR   28-OCT-1999;   99US-0429695.
PR   03-DEC-1999;   99US-0454399.
PR   12-JAN-2000; 2000US-0481794.
XX
PA   (PHAA ) PHARMACIA & UPJOHN CO.
XX
PI   Vogeli G,  Wood LS,  Merchant K;
XX
DR   WPI; 2001-328653/34.
DR   N-PSDB; AAD06502.
XX
PT   Seven transmembrane receptor polypeptides and polynucleotides, useful
PT   for treating neurological or psychiatric disorders, e.g. schizophrenia,
PT   as well as for identifying compounds useful for treating schizophrenia
PT   -
XX
PS   Claim 1; Page 7-9; 215pp; English.
XX
CC   The invention relates to human G protein-coupled receptor (GPCR) and
CC   their corresponding DNA molecules. GPCR is also referred as seven
CC   transmembrane receptor. G protein-coupled receptor protein is useful for
CC   treating neurological disorder, particularly schizophrenia. GPCR protein
CC   is also useful for identifying compounds useful for treating
CC   schizophrenia. These compounds are also useful for treating other
CC   neurological and psychiatric diseases, e.g. depression, anxiety, bipolar
CC   disease, affective disorders, attention deficit hyperactivity disorder/
CC   attention deficit disorder, epilepsy, neuritis, neurasthenia, neuropathy,
CC   neurosis, Alzheimer's disease, Parkinson's disease, migraine and senile
CC   dementia. The invention also provides genetic screening procedures that
CC   entail analysing a person's genome with respect to GPCR. The vectors are
CC   useful for the recombinant production of the GPCR's. The present sequence
CC   is human CON103 G protein-coupled receptor (GPCR) protein.
XX
SQ   Sequence   384 AA;

  Query Match             3.4%;  Score 9;  DB 22;  Length 384;
  Best Local Similarity   100.0%;  Pred. No. 10;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      12 PSPSLSSSV 20
           |||||||||
Db       9 PSPSLSSSV 17


RESULT 18
AAU74911
ID   AAU74911 standard; Protein; 384 AA.
XX
AC   AAU74911;
XX
DT   09-APR-2002  (first entry)
XX
DE   Amino acid sequence of human G-protein coupled receptor TGR92 protein.
XX
KW   Human; G-protein coupled; receptor; GPCR; TGR92; kidney disease;
KW   signal transduction modulator; cerebral cavernous malformation;
KW   hyperlipidemia; obesity; dyslexia; cardiac myxoma; renal failure;
KW   nephritis; hypertension; liver disease; cirrhosis; blood disorder;
KW   spleen-associated disorder; immune disorder.
XX
OS   Homo sapiens.
XX
PN   WO200200719-A2.
XX
PD   03-JAN-2002.
XX
PF   25-JUN-2001; 2001WO-US20363.
XX
PR   23-JUN-2000; 2000US-213461P.
XX
PA   (TULA-) TULARIK INC.
XX
PI   Lin DC,  Zhao J,  Chen J,  Cutler G;
XX
DR   WPI; 2002-147880/19.
DR   N-PSDB; ABK12964.
XX
PT   New G-protein coupled receptor polypeptides, useful for identifying
PT   modulators of signal transduction for treating kidney disease,
PT   hyperlipidemia, obesity, dyslexia and cardiac myxoma  -
XX
PS   Claim 26; Page 67; 78pp; English.
XX
CC   The present invention relates to a new G-protein coupled receptor (GPCR)
CC   polypeptide comprising greater than 70% amino acid sequence identity to
CC   the amino acid sequence of human GPCRs TGR62, TGR21, TGR130.1, TGR130.2,
CC   human TGR213 or TGR92, 80% amino acid sequence identity to mouse TGR18
CC   or 90% amino acid sequence identity to human novel edg receptor protein,
CC   as defined in the specification. The GPCR covalently linked to a solid
CC   phase is useful for identifying a compound that modulates signal
CC   transduction. The identified compounds are useful for treating
CC   kidney disease, cerebral cavernous malformations, hyperlipidemia,
CC   obesity, dyslexia and cardiac myxoma. The molecules of the invention are
CC   useful for diagnosing disorders or conditions such as kidney-related
CC   conditions or diseases such as renal failure, nephritis, nephrotic
CC   syndrome, asymptomatic urinary abnormalities, renal tubule defects,
CC   hypertension and nephrolithiasis, liver-related disease or condition
CC   e.g. cirrhosis, infiltrations, lesions, functional disorders and jaundice
CC   and spleen-associated disorders or conditions e.g. splenic enlargement,
CC   immune disorders, blood disorders and others. Modulation of the
CC   polypeptide of the invention is useful to treat or prevent any of the
CC   above conditions or diseases. The present amino acid sequence represents
```

CC the human GPCR TGR92 protein of the invention. This sequence is one of
CC seven novel G protein coupled receptors of the invention (AAU74904-
CC AAU74911).
XX
SQ Sequence 384 AA;

Query Match 3.4%; Score 9; DB 23; Length 384;
Best Local Similarity 100.0%; Pred. No. 10;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 12 PSPSLSSSV 20
|||||||||
Db 9 PSPSLSSSV 17

RESULT 19
AAW88460
ID AAW88460 standard; Protein; 423 AA.
XX
AC AAW88460;
XX
DT 10-MAY-1999 (first entry)
XX
DE Human 7-transmembrane receptor HEOAD54.
XX
KW HEOAD54; 7-transmembrane receptor; G protein coupled receptor;
KW signal transduction; human; infection; HIV-1; HIV-2; pain; cancer;
KW anorexia; bulimia; asthma; Parkinson's disease; hypotension;
KW hypertension; acute heart failure; urinary retention; osteoporosis;
KW angina pectoris; myocardial infarction; ulcer; allergy;
KW benign prostatic hypertrophy; anxiety; schizophrenia; delirium;
KW manic depression; dementia, severe mental retardation; dyskinesia;
KW Huntington's disease; Gilles de la Tourette's syndrome; diagnosis;
KW therapy; vaccine.
XX
OS Homo sapiens.
XX
PN EP892051-A2.
XX
PD 20-JAN-1999.
XX
PF 27-MAY-1998; 98EP-0304192.
XX
PR 23-OCT-1997; 97US-0955713.
PR 18-JUN-1997; 97US-0060124.
XX
PA (SMIK) SMITHKLINE BEECHAM CORP.
XX
PI Bergsma DJ, Halsey WS, Mooney JL, Sathe GM;
XX
DR WPI; 1999-083568/08.
DR N-PSDB; AAX06947.
XX
PT New G-protein coupled receptor (HEOAD54) polypeptide and
PT polynucleotide - useful as diagnostic reagents, and for prevention
PT and treatment of HIV infections and cancer
XX
PS Claim 11; Page 20-21; 25pp; English.
XX
CC This is the amino acid sequence of a novel human G protein coupled
CC receptor, designated HEOAD54, as deduced from a cDNA clone (see
CC AAX06947) isolated from an eosinophil library. A method is claimed
CC for diagnosing susceptibility to disease resulting from mutation of
CC the HEOAD54 gene or imbalance in HEOAD54 polypeptide expression
CC levels. HEOAD45 agonists/antagonists can be used to activate/inhibit
CC HEOAD54 activity. Direct administration of antisense sequences is
CC used to prevent expression, while administration of HEOAD54 is used
CC to treat conditions associated with a lack of HEOAD54 protein. Gene
CC therapy may also be used to affect endogenous HEOAD54 polypeptide
CC expression. HEOAD54 polypeptides can be administered directly or
CC as a vaccine to inoculate against disease. Diseases diagnosed,
CC prevented and treated include bacterial, fungal, protozoan and
CC viral infections, particularly HIV-1 or HIV-2 infections, pain,
CC cancers, anorexia, bulimia, asthma, Parkinson's disease, acute
CC heart failure, hypotension, hypertension, urinary retention,
CC osteoporosis, angina pectoris, myocardial infarction, ulcer,
CC allergy, benign prostatic hypertrophy, and psychotic and
CC neurological disorders including anxiety, schizophrenia, manic
CC depression, delirium, dementia, severe mental retardation and
CC dyskinesias, such as Huntington's disease or Gilles de la
CC Tourette's syndrome.
XX
SQ Sequence 423 AA;

Query Match 3.4%; Score 9; DB 20; Length 423;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 12 PSPSLSSSV 20
|||||||||
Db 48 PSPSLSSSV 56

RESULT 20
AAG78785
ID AAG78785 standard; Protein; 423 AA.
XX
AC AAG78785;
XX
DT 10-JAN-2002 (first entry)
XX
DE Human opioid-type receptor 1.
XX
KW Human; G-protein coupled receptor; opioid-type receptor 1; OTR1;
KW neurotransmission.
XX
OS Homo sapiens.
XX
PN DE10021475-A1.
XX
PD 08-NOV-2001.
XX
PF 03-MAY-2000; 2000DE-1021475.
XX
PR 03-MAY-2000; 2000DE-1021475.
XX
PA (BRUE/) BRUESS M.
PA (BOEN/) BOENISCH H.
XX
PI Bruess M, Boenisch H;
XX
DR WPI; 2001-657613/76.
DR N-PSDB; AAI71608, AAI71609.
XX
PT New opioid-type receptor-1 gene, OTR1, useful for diagnosis and
PT treatment of OTR1-related diseases -
XX
PS Disclosure; Page 5; 6pp; German.
XX
CC The present invention provides the protein, cDNA and genomic DNA
CC sequences of human G-protein coupled receptor opioid-type receptor 1
CC (OTR1). The protein is involved in neurotransmission, and the sequences
CC can be used in the treatment of OTR1 related diseases. The present
CC sequence is the OTR1 protein.
XX
SQ Sequence 423 AA;

Query Match 3.4%; Score 9; DB 22; Length 423;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 12 PSPSLSSSV 20
|||||||||
Db 48 PSPSLSSSV 56

```
RESULT 21
AAU04365
ID   AAU04365 standard; Protein; 423 AA.
XX
AC   AAU04365;
XX
DT   23-OCT-2001  (first entry)
XX
DE   Human G-protein coupled receptor, hRUP11.
XX
KW   Human; G-protein coupled receptor; GPCR; hRUP11; agonist;
KW   inverse agonist; lung cancer.
XX
OS   Homo sapiens.
XX
PN   WO200136471-A2.
XX
PD   25-MAY-2001.
XX
PF   16-NOV-2000; 2000WO-US31509.
XX
PR   17-NOV-1999;   99US-0166088.
PR   17-NOV-1999;   99US-0166099.
PR   17-NOV-1999;   99US-0166369.
PR   23-DEC-1999;   99US-0171900.
PR   23-DEC-1999;   99US-0171901.
PR   23-DEC-1999;   99US-0171902.
PR   11-FEB-2000; 2000US-0181749.
PR   14-MAR-2000; 2000US-0189258.
PR   14-MAR-2000; 2000US-0189259.
PR   10-APR-2000; 2000US-0195898.
PR   10-APR-2000; 2000US-0195899.
PR   10-APR-2000; 2000US-0196078.
PR   28-APR-2000; 2000US-0200419.
PR   12-MAY-2000; 2000US-0203630.
PR   12-JUN-2000; 2000US-0210741.
PR   12-JUN-2000; 2000US-0210982.
PR   21-AUG-2000; 2000US-0226760.
PR   26-SEP-2000; 2000US-0235418.
PR   26-SEP-2000; 2000US-0235779.
PR   20-OCT-2000; 2000US-0242332.
PR   20-OCT-2000; 2000US-0242343.
XX
PA   (AREN-) ARENA PHARM INC.
XX
PI   Chen R,  Dang HT,  Lowitz KP;
XX
DR   WPI; 2001-355616/37.
DR   N-PSDB; AAS07938.
XX
PT   Endogenous and non-endogenous versions of human G-protein coupled
PT   receptors for direct identification of candidate compounds as agonists,
PT   inverse agonists or partial agonists for use as therapeutic agents -
XX
PS   Claim 13; Page 94-96; 160pp; English.
XX
CC   The sequence represents a human G-protein coupled receptor (GPCR),
CC   hRUP11. The endogenous and non-endogenous, constitutively activated
CC   versions of human G-protein coupled receptors (GPCR), are useful for
CC   direct identification of candidate compounds as receptor agonists,
CC   inverse agonists or partial agonists having applicability as therapeutic
CC   agents for treating diseases related to GPCR, e.g. lung cancer.
CC   Non-endogenous version of human GPCRs are also utilized in research
CC   settings and in vitro and in vivo system, incorporating GPCRs can be
CC   utilised to elucidate and understand the roles these receptors
CC   play in the human condition, both normal and diseased.
XX
SQ   Sequence   423 AA;

  Query Match             3.4%;  Score 9;  DB 22;  Length 423;
  Best Local Similarity   100.0%;  Pred. No. 11;
  Matches    9;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      12 PSPSLSSSV 20
           |||||||||
Db      48 PSPSLSSSV 56


RESULT 22
AAY94339
ID   AAY94339 standard; Protein; 455 AA.
XX
AC   AAY94339;
XX
DT   22-AUG-2000  (first entry)
XX
DE   Human cell surface receptor protein #6.
XX
KW   Human; HCSRP; cytostatic; antiarthritic; antirheumatic; antiasthmatic;
KW   immunosuppressive; antiarteriosclerotic; antibacterial; antiparasitic;
KW   neuroprotective; nootropic; anticonvulsant; cancer; leukaemia;
KW   melanoma; rheumatoid arthritis; asthma; atherosclerosis; akathesia;
KW   Alzheimer's diseases; multiple sclerosis; epilepsy.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Domain          128..150
FT                   /label= Transmembrane_domain
FT   Domain          291..310
FT                   /label= Transmembrane_domain
FT   Domain          141..387
FT                   /label= Rhodopsin_GPCR_domain
FT   Region          126..150
FT                   /note= "Rhodopsin signature"
FT   Region          159..180
FT                   /note= "Rhodopsin signature"
FT   Region          204..226
FT                   /note= "Rhodopsin signature"
FT   Region          325..349
FT                   /note= "Rhodopsin signature"
FT   Region          369..395
FT                   /note= "Rhodopsin signature"
FT   Region          22
FT                   /note= "potential phosphorylation site"
FT   Region          53
FT                   /note= "potential phosphorylation site"
FT   Region          76
FT                   /note= "potential glycosylation site"
FT   Region          189
FT                   /note= "potential phosphorylation site"
FT   Region          206
FT                   /note= "potential phosphorylation site"
FT   Region          207
FT                   /note= "potential glycosylation site"
FT   Region          271
FT                   /note= "potential phosphorylation site"
FT   Region          281
FT                   /note= "potential phosphorylation site"
FT   Region          310
FT                   /note= "potential phosphorylation site"
FT   Region          380
FT                   /note= "potential phosphorylation site"
FT   Region          430
FT                   /note= "potential phosphorylation site"
XX
PN   WO200028032-A2.
XX
PD   18-MAY-2000.
XX
PF   12-NOV-1999;   99WO-US26742.
XX
PR   12-NOV-1998;   98US-0191280.
PR   07-DEC-1998;   98US-0206647.
PR   08-MAR-1999;   99US-0123404.
XX
```

PA (INCY-) INCYTE PHARM INC.
XX
PI Tang YT, Corley NC, Guegler KJ, Yue H, Baughn MR, Lal P;
PI Hillman JL, Bandman O, Azimzai Y, Au-Young J;
XX
DR WPI; 2000-376546/32.
DR N-PSDB; AAA27049.
XX
PT New human cell surface receptor protein and polynucleotide useful for
PT diagnosis, prevention and treatment of cancer, immune disorders,
PT infection and neuronal disorders -
XX
PS Claim 1; Page 79-80; 97pp; English.
XX
CC The present sequence is a novel human cell surface receptor protein
CC (HCSRP) designated HCSRP-6. The nucleotide sequence was identified in
CC Incyte Clone 2851578 from the cDNA library BRSTTUT13, which was made
CC from RNA isolated from breast tumour tissue. A number of Incyte Clones
CC were used to assemble the consensus sequence. BLAST analysis showed that
CC the sequence is homologous to rhodopsin-like GPCR/HM74 g219867 isoform
CC g507827. HCSRP and its antagonist are useful for preventing or
CC treating disorders associated with decreased or increased expression or
CC activity of HCSRP. Such disorders include cancers such as leukaemia and
CC melanoma, immune disorders such as rheumatoid arthritis, asthma and
CC atherosclerosis, bacterial and parasitic infections and neuronal
CC disorders such as akathesia, Alzheimer's disease, multiple sclerosis and
CC epilepsy. Polynucleotides encoding HSCRPs may be used as hybridisation
CC probes to diagnose these conditions. Anti-HCSRP antibodies may be used
CC as antagonists, as a targeting or delivery mechanism for bringing
CC pharmaceutical agents into contact with cells or tissues expressing
CC HCSRP and for diagnosis of HCSRP-related disorders. HCSRP and its
CC catalytic or immunogenic fragments are useful for drug screening using
CC libraries of compounds.
XX
SQ Sequence 455 AA;

Query Match 3.4%; Score 9; DB 21; Length 455;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 12 PSPSLSSSV 20
|||||||||
Db 80 PSPSLSSSV 88

RESULT 23
ABB57777
ID ABB57777 standard; Protein; 552 AA.
XX
AC ABB57777;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 123.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL01880.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Disclosure; SEQ ID NO 123; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 552 AA;

Query Match 3.4%; Score 9; DB 22; Length 552;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 165 TFPSLQALV 173
|||||||||
Db 233 TFPSLQALV 241

RESULT 24
ABB66713
ID ABB66713 standard; Protein; 552 AA.
XX
AC ABB66713;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 26931.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL10816.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Disclosure; SEQ ID NO 26931; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of

CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 552 AA;

Query Match 3.4%; Score 9; DB 22; Length 552;
Best Local Similarity 100.0%; Pred. No. 14;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 165 TFPSLQALV 173
|||||||||
Db 233 TFPSLQALV 241

RESULT 25
AAM25233
ID AAM25233 standard; Protein; 55 AA.
XX
AC AAM25233;
XX
DT 16-OCT-2001 (first entry)
XX
DE Human protein sequence SEQ ID NO:748.
XX
KW Human; cancer; ulcer; HIV infection; human immunodeficiency virus;
KW antiinflammatory; antirheumatic; antiarthritic; immunosuppressive;
KW antibacterial; endocrine; cardiant; central nervous system; virucide;
KW anti-HIV; fungicide; antimutagen; cardiovascular; antianaemic; anaemia;
KW antiaggregant; haemostatic; vulnerary; antiulcer; osteopathic; eczema;
KW dermatological; antiallergic; antiasthmatic; antidiabetic; cytostatic;
KW neuroprotective; antidepressant; nootropic; antiparkinsonian; infection;
KW immunostimulant; gene therapy; antisense therapy; vaccine; inflammation;
KW antianaphylactic; rheumatoid arthritis; septic shock; pancreatitis;
KW cardiac dysfunction; neuropathology; cardiac anaphylaxis; autoimmunity;
KW genetic disease; haematopoietic disorder; platelet disorder; asthma;
KW thrombocytopaenia; osteoporosis; severe combined immunodeficiency;
KW allergic rhinitis; diabetes; multiple sclerosis; depression;
KW Alzheimer's disease; Parkinson's disease; neurodegenerative disorder;
KW neurological disorder.
XX
OS Homo sapiens.
XX
PN WO200153455-A2.
XX
PD 26-JUL-2001.
XX
PF 22-DEC-2000; 2000WO-US35017.
XX
PR 23-DEC-1999; 99US-0471275.
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-457603/49.
DR N-PSDB; AAH99174.
XX
PT Isolated human polynucleotides encoding polypeptides, useful for the
PT treatment and diagnosis of e.g. cancer, ulcers and HIV infection -
XX
PS Claim 20; Page 181; 1217pp; English.
XX
CC AAH99166 to AAH99904 encode the human proteins given in AAM25225 to
CC AAM25963. The proteins can have activities based on the tissues and
CC cells they are expressed in, such as: antiinflammatory; antirheumatic;
CC antiarthritic; immunosuppressive; antibacterial; endocrine; cardiant;
CC central nervous system; virucide; anti-HIV; fungicide; antimutagen;
CC cardiovascular; antianaemic; antiaggregant; haemostatic; vulnerary;
CC antiulcer; osteopathic; dermatological; antiallergic; antiasthmatic;
CC antidiabetic; cytostatic; neuroprotective; antidepressant; nootropic;
CC antiparkinsonian; and immunostimulant. The proteins and polynucleotides
CC encoding them can be used in gene therapy, antisense therapy and vaccine
CC production, The proteins and polynucleotides are useful for screening for
CC agonists or antagonists of a protein and for the treatment and diagnosis
CC of disorders associated with the activity of a protein e.g. inflammation,
CC rheumatoid arthritis, septic shock, pancreatitis, cardiac dysfunction,
CC neuropathology, cardiac anaphylaxis, viral, bacterial, HIV and fungal
CC infections, autoimmunity, genetic diseases, haematopoietic disorders,
CC anaemia, platelet disorders, thrombocytopaenia, wounds, burns, ulcers,
CC osteoporosis, severe combined immunodeficiency, eczema, allergic
CC rhinitis, asthma, diabetes, cancer, multiple sclerosis, depression,
CC Alzheimer's disease, Parkinson's disease, neurodegenerative and
CC neurological disorders.
XX
SQ Sequence 55 AA;

Query Match 3.1%; Score 8; DB 22; Length 55;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 128 GSYSLSVR 135
||||||||
Db 13 GSYSLSVR 20

RESULT 26
AAG12482
ID AAG12482 standard; Protein; 84 AA.
XX
AC AAG12482;
XX
DT 17-OCT-2000 (first entry)
XX
DE Zea mays protein fragment SEQ ID NO: 11611.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence; corn.
XX
OS Zea mays subsp. mays.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.

PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.

PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 3.1%; Score 8; DB 21; Length 84;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SLPSRRKS 10
||||||||
Db 44 SLPSRRKS 51

RESULT 27
AAM90260
ID AAM90260 standard; Protein; 90 AA.
XX
AC AAM90260;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:17853.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.

```
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
DR   N-PSDB; AAK63041.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis -
XX
PS   Claim 11; SEQ ID NO 17853; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence   90 AA;

  Query Match             3.1%;  Score 8;  DB 22;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 23;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     13 SPSLSSSV 20
          ||||||||
Db      4 SPSLSSSV 11


RESULT 28
AAW03989
ID   AAW03989 standard; Peptide; 106 AA.
XX
AC   AAW03989;
XX
DT   30-APR-1997  (first entry)
XX
DE   SH2 domain from human Grb-2 (amino acids 58-159).
XX
KW   Polymerase chain reaction; PCR; amplify; primer; chicken; src;
KW   SH2 domain; DET1; DET2; erythropoiesis; anaemia; haematopoiesis;
KW   antagonist.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         103..106
FT                   note= "C-terminal extension"
XX
PN   EP728482-A2.
XX
PD   28-AUG-1996.
XX
PF   07-FEB-1996;   96EP-0200269.
XX
PR   29-DEC-1995;   95US-0581089.
PR   10-FEB-1995;   95US-0386381.
PR   07-MAR-1995;   95US-0400220.
PR   30-JUN-1995;   95US-0497357.
PR   11-OCT-1995;   95US-0540680.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Dunnington DJ;
XX
DR   WPI; 1996-386024/39.
XX
PT   Use of selective antagonist of haematopoietic acid phosphatase SH2
PT   domain - with no significant affinity for other SH2 domains, to
PT   increase erythropoiesis and haematopoiesis, esp. for treatment of
PT   anaemia
XX
PS   Example 4; Page 42-43; 46pp; English.
XX
CC   The sequences given in AAW03986-89 represent SH2 domain peptides with
CC   C-terminal extensions which were used  in the isolation of a compound
CC   for improving erythropoiesis.  The compound may be used for the
CC   treatment of anaemia or to enhance haematopoiesis.  The isolated
CC   compound antagonises the hcp SH2 domain without side effects caused by
CC   non-specific inhibition of other SH2 domains.
XX
SQ   Sequence   106 AA;

  Query Match             3.1%;  Score 8;  DB 17;  Length 106;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    116 GAFLIRES 123
          ||||||||
Db     24 GAFLIRES 31


RESULT 29
AAW02127
ID   AAW02127 standard; Protein; 106 AA.
XX
AC   AAW02127;
XX
DT   28-OCT-1996  (first entry)
```

```
XX
DE   Human Grb2 SH2 domain with C-terminal extension.
XX
KW   Bone resorption disease; osteoporosis; src SH2 domain antagonist;
KW   src homology 2 domain; glutathione-s-transferase; GST; Grb2 SH2.
XX
OS   Chimeric Homo sapiens;
OS   Chimeric synthetic.
XX
FH   Key             Location/Qualifiers
FT   Protein         1..102
FT                   /label= Grb2-SH2
FT   Peptide         103..106
FT                   /label= C-terminal_extension
XX
PN   EP727211-A1.
XX
PD   21-AUG-1996.
XX
PF   07-FEB-1996;    96EP-0200270.
XX
PR   29-DEC-1995;    95US-0580868.
PR   10-FEB-1995;    95US-0386381.
PR   07-MAR-1995;    95US-0400220.
PR   30-JUN-1995;    95US-0497357.
PR   11-OCT-1995;    95US-0541080.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Dunnington DJ;
XX
DR   WPI; 1996-372674/38.
XX
PT   Use of selective src SH2 domain ligand - to prepare medicament for
PT   treating bone resorption disease
XX
PS   Example 11; Page 42-43; 47pp; English.
XX
CC   A protein construct (AAW02127) comprises the human Grb2 domain
CC   (amino acids 58-159) with a C-terminal extension.  DNA encoding
CC   the construct was incorporated into a pGEX-2T vector to yield a
CC   sequence coding for GST-X-Grb2 SH2.  This, and similar fusion
CC   proteins (see also AAW02119-21 and AAW02125-26) incorporating other
CC   human SH2 domains, can be used in binding assays to determine the
CC   specificity of cpds. to inhibit SH2 domains; cpds. that selectively
CC   inhibit the human src SH2 domain are useful in treating bone
CC   resorption diseases such as osteoporosis.
XX
SQ   Sequence   106 AA;

  Query Match             3.1%;  Score 8;  DB 17;  Length 106;
  Best Local Similarity   100.0%;  Pred. No. 27;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy     116 GAFLIRES 123
           ||||||||
Db      24 GAFLIRES 31


RESULT 30
AAG12481
ID   AAG12481 standard; Protein; 110 AA.
XX
AC   AAG12481;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Zea mays protein fragment SEQ ID NO: 11610.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence; corn.
XX
OS   Zea mays subsp. mays.
XX
PN   EP1033405-A2.
XX
PD   06-SEP-2000.
XX
PF   25-FEB-2000; 2000EP-0301439.
XX
PR   25-FEB-1999;    99US-0121825.
PR   05-MAR-1999;    99US-0123180.
PR   09-MAR-1999;    99US-0123548.
PR   23-MAR-1999;    99US-0125788.
PR   25-MAR-1999;    99US-0126264.
PR   29-MAR-1999;    99US-0126785.
PR   01-APR-1999;    99US-0127462.
PR   06-APR-1999;    99US-0128234.
PR   08-APR-1999;    99US-0128714.
PR   16-APR-1999;    99US-0129845.
PR   19-APR-1999;    99US-0130077.
PR   21-APR-1999;    99US-0130449.
PR   23-APR-1999;    99US-0130510.
PR   23-APR-1999;    99US-0130891.
PR   28-APR-1999;    99US-0131449.
PR   30-APR-1999;    99US-0132048.
PR   30-APR-1999;    99US-0132407.
PR   04-MAY-1999;    99US-0132484.
PR   05-MAY-1999;    99US-0132485.
PR   06-MAY-1999;    99US-0132486.
PR   06-MAY-1999;    99US-0132487.
PR   07-MAY-1999;    99US-0132863.
PR   11-MAY-1999;    99US-0134256.
PR   14-MAY-1999;    99US-0134218.
PR   14-MAY-1999;    99US-0134219.
PR   14-MAY-1999;    99US-0134221.
PR   14-MAY-1999;    99US-0134370.
PR   18-MAY-1999;    99US-0134768.
PR   19-MAY-1999;    99US-0134941.
PR   20-MAY-1999;    99US-0135124.
PR   21-MAY-1999;    99US-0135353.
PR   24-MAY-1999;    99US-0135629.
PR   25-MAY-1999;    99US-0136021.
PR   27-MAY-1999;    99US-0136392.
PR   28-MAY-1999;    99US-0136782.
PR   01-JUN-1999;    99US-0137222.
PR   03-JUN-1999;    99US-0137528.
PR   04-JUN-1999;    99US-0137502.
PR   07-JUN-1999;    99US-0137724.
PR   08-JUN-1999;    99US-0138094.
PR   10-JUN-1999;    99US-0138540.
PR   10-JUN-1999;    99US-0138847.
PR   14-JUN-1999;    99US-0139119.
PR   16-JUN-1999;    99US-0139452.
PR   16-JUN-1999;    99US-0139453.
PR   17-JUN-1999;    99US-0139492.
PR   18-JUN-1999;    99US-0139454.
PR   18-JUN-1999;    99US-0139455.
PR   18-JUN-1999;    99US-0139456.
PR   18-JUN-1999;    99US-0139457.
PR   18-JUN-1999;    99US-0139458.
PR   18-JUN-1999;    99US-0139459.
PR   18-JUN-1999;    99US-0139460.
PR   18-JUN-1999;    99US-0139461.
PR   18-JUN-1999;    99US-0139462.
PR   18-JUN-1999;    99US-0139463.
PR   18-JUN-1999;    99US-0139750.
PR   18-JUN-1999;    99US-0139763.
PR   21-JUN-1999;    99US-0139817.
PR   22-JUN-1999;    99US-0139899.
PR   23-JUN-1999;    99US-0140353.
PR   23-JUN-1999;    99US-0140354.
PR   24-JUN-1999;    99US-0140695.
PR   28-JUN-1999;    99US-0140823.
PR   29-JUN-1999;    99US-0140991.
```

PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 3.1%; Score 8; DB 21; Length 110;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SLPSRRKS 10
||||||||
Db 70 SLPSRRKS 77

RESULT 31
AAM84060
ID AAM84060 standard; Protein; 167 AA.
XX
AC AAM84060;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen SEQ ID NO:11653.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX

PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
DR N-PSDB; AAK56841.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and

PT metastasis -
XX
PS Claim 11; SEQ ID NO 11653; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 167 AA;

Query Match 3.1%; Score 8; DB 22; Length 167;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 12 PSPSLSSS 19
||||||||
Db 101 PSPSLSSS 108

RESULT 32
AAR85918
ID AAR85918 standard; Protein; 217 AA.
XX
AC AAR85918;
XX
DT 16-MAY-1996 (first entry)
XX
DE Human GRB-2.
XX
KW GRB-2; growth factor receptor bound; tyrosine kinase; regulation;
KW cell growth; cellular metabolism; screening; signal transduction;
KW cancer; diabetes; CORT technique; cloning of receptor targets.
XX
OS Homo sapiens.
XX
PN WO9524426-A1.
XX
PD 14-SEP-1995.
XX
PF 13-MAR-1995; 95WO-US03385.
XX
PR 11-MAR-1994; 94US-0208887.
XX
PA (UYNY) UNIV NEW YORK STATE.
XX
PI Margolis BL, Schlessinger J, Skolnik EY;
XX
DR WPI; 1995-328235/42.
DR N-PSDB; AAT07167.
XX
PT DNA encoding tyrosine kinase-binding proteins - used to screen
PT agents capable of modulating cell growth or cellular metabolism
XX
PS Disclosure; Fig 26A-C; 215pp; English.
XX
CC Using a new cloning technique, CORT (cloning of receptor targets)
CC several new tyrosine kinase (TK) binding proteins were isolated. Growth
CC factor receptor bound proteins GRB-1,GRB-2, GRB-3, GRB-4, GRB-7 and
CC GRB-10 were isolated using this method. This sequence represents GRB-2.
CC The proteins bind to a tyrosine-phosphorylated domain of a eukaryotic
CC TK. GRB proteins can be used for screening agents which are capable
CC of modulating cell growth that occurs via signal transduction through
CC TKs. Such agents can be used to prevent or inhibit cell growth or to
CC counteract tumour development. GRB proteins are also useful for
CC identifying susceptibility to diseases asociated with alterations in
CC cellular metabolism mediated by TK pathways e.g. cancer and diabetes.
XX
SQ Sequence 217 AA;

Query Match 3.1%; Score 8; DB 16; Length 217;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 116 GAFLIRES 123
||||||||
Db 81 GAFLIRES 88

RESULT 33
AAW18063
ID AAW18063 standard; Protein; 217 AA.
XX
AC AAW18063;
XX
DT 06-DEC-1997 (first entry)
XX
DE Growth factor receptor-binding protein 2 homologue Grb2-1.
XX
KW Growth factor receptor-binding protein 2 homologue; Grb2-1; human;
KW signal transduction; antagonist; antisense; immunosuppressive;
KW autoimmune disease; transplant rejection; agonist; HIV; infection;
KW cancer; diagnosis; gene therapy.
XX
OS Homo sapiens.
XX
PN WO9720573-A1.
XX
PD 12-JUN-1997.
XX
PF 04-DEC-1995; 95WO-US15883.
XX
PR 04-DEC-1995; 95WO-US15883.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
PA (JOSL-) JOSLIN DIABETES CENT INC.
PA (SMIK) SMITHKLINE BEECHAM CORP.
XX
PI Dunnington D, Ni J, Shoelson SE;
XX
DR WPI; 1997-319539/29.
DR N-PSDB; AAT67275.
XX
PT Growth factor receptor-binding protein 2 homologue and related DNA -
PT used to develop products for diagnosis and therapy of, e.g.
PT autoimmune diseases, transplant rejection, HIV infection or cancer
XX
PS Claim 4; Page 38-39; 57pp; English.
XX
CC This polypeptide comprises a human growth factor receptor-binding
CC protein 2 homologue, Grb2-1 (AAW18063), that exhibits T-cell
CC specificity. Its amino acid sequence was deduced from a cDNA
CC sequence (AAT67275) originally derived from a human tonsil cDNA
CC library. It shows 58% identity with the human Grb2 amino acid
CC sequence. Methods are claimed for producing pure human Grb2-1
CC protein in a recombinant host cell, for treating conditions related
CC to insufficient Grb2-1 protein function, and for identifying
CC compounds that modulate Grb2-1 activity, such as substances that
CC modulate the ras pathway in T-lymphocytes by affecting the binding
CC of Grb2-1 to the cell membrane. Modulation of Grb2-1 function can
CC be used to affect immune system function by affecting T-cell
CC proliferation pathways. Antagonists have immunosuppressive
CC activities and can be used to treat and prevent autoimmune diseases

```
CC   and transplant rejection.  Agonists can be used to treat immune
CC   deficiency states such as HIV infection or cancer.
XX
SQ   Sequence   217 AA;

  Query Match             3.1%;  Score 8;  DB 18;  Length 217;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    116 GAFLIRES 123
          ||||||||
Db     81 GAFLIRES 88


RESULT 34
AAW14004
ID   AAW14004 standard; Protein; 217 AA.
XX
AC   AAW14004;
XX
DT   24-JUN-1997  (first entry)
XX
DE   Human GRB2.
XX
KW   SH2-containing inositol phosphatase; SHIP;
KW   inositol polyphosphate 5-phosphatase; src homology domain 2;
KW   SH2 domain; signal transduction; leukaemia; cancer; Grb2;
KW   epidermal growth factor receptor binding protein.
XX
OS   Homo sapiens.
XX
PN   WO9712039-A2.
XX
PD   03-APR-1997.
XX
PF   27-SEP-1996;   96WO-CA00655.
XX
PR   14-JUN-1996;   96US-0664962.
PR   27-SEP-1995;   95US-0006063.
PR   30-NOV-1995;   95US-0007788.
PR   09-APR-1996;   96US-0015217.
XX
PA   (KRYS/) KRYSTAL G.
XX
PI   Krystal G;
XX
DR   WPI; 1997-212898/19.
DR   N-PSDB; AAT60302.
XX
PT   Inositol polyphosphate-5-phosphatase having SH2 domain - useful for
PT   treating cancer and other conditions involving abnormal signalling
XX
PS   Disclosure; Page 47-48; 89pp; English.
XX
CC   Human epidermal growth factor receptor binding protein GRB2
CC   (AAW14003) is an src homology domain 3 (SH3) protein that is capable
CC   of binding to novel murine and human SHIP (SH2-containing inositol
CC   phosphatase) proteins (see also AAW14002-03).  It can be used in
CC   methods for identifying agonists and antagonists of SHIP.
XX
SQ   Sequence   217 AA;

  Query Match             3.1%;  Score 8;  DB 18;  Length 217;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    116 GAFLIRES 123
          ||||||||
Db     81 GAFLIRES 88


RESULT 35
AAW42070
ID   AAW42070 standard; Protein; 217 AA.
XX
AC   AAW42070;
XX
DT   04-JUN-1998  (first entry)
XX
DE   Growth factor receptor-bound protein 2.
XX
KW   Growth factor receptor-bound protein 2; Grb-2; CML; bcr-abl;
KW   translation initiation site; chronic myelogenous leukaemia; cancer.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Domain          5..54
FT                   /label= SH3
FT   Domain          60..158
FT                   /label= SH2
FT   Domain          163..208
FT                   /label= SH3
XX
PN   WO9801547-A1.
XX
PD   15-JAN-1998.
XX
PF   08-JUL-1997;   97WO-US10101.
XX
PR   08-JUL-1996;   96US-0679437.
XX
PA   (TEXA ) UNIV TEXAS SYSTEM.
XX
PI   Arlinghaus RB,  Lopez-Berestein G,  Tari AM;
XX
DR   WPI; 1998-110229/10.
DR   N-PSDB; AAV09213.
XX
PT   Use of anti-sense oligo:nucleotide(s) to Grb2 or Crkl nucleic acids
PT   - for inhibiting growth of cancer cells in treatment of cancers,
PT   particularly chronic myelogenous leukaemia
XX
PS   Disclosure; Fig 4; 47pp; English.
XX
CC   This is a polypeptide sequence of Grb-2. Translation of Grb-2 cDNA
CC   can be inhibited by oligonucleotides of specific composition that
CC   hybridise to its translation initiation site (see AAV09215).
CC   The oligonucleotide compositions can be used for treating, particularly
CC   chronic myelogenous leukaemia (CML).
XX
SQ   Sequence   217 AA;

  Query Match             3.1%;  Score 8;  DB 19;  Length 217;
  Best Local Similarity   100.0%;  Pred. No. 49;
  Matches    8;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy    116 GAFLIRES 123
          ||||||||
Db     81 GAFLIRES 88


RESULT 36
ABB57107
ID   ABB57107 standard; Protein; 217 AA.
XX
AC   ABB57107;
XX
DT   07-MAR-2002  (first entry)
XX
DE   Mouse ischaemic condition related protein sequence SEQ ID NO:244.
XX
KW   Mouse; ischaemia; compressive ischaemia; occlusive ischaemia;
KW   vasospastic ischaemia; ischaemic condition; ischaemic disease.
XX
OS   Mus musculus.
```

XX
PN WO200188188-A2.
XX
PD 22-NOV-2001.
XX
PF 18-MAY-2001; 2001WO-JP04192.
XX
PR 18-MAY-2000; 2000JP-0145977.
XX
PA (UYNI-) UNIV NIHON SCHOOL JURIDICAL PERSON.
XX
PI Ishikawa K, Asai S, Takahashi Y, Nagata T, Ishii Y;
XX
DR WPI; 2002-034733/04.
DR N-PSDB; ABI99357.
XX
PT Examining the ischemic condition (e.g. occlusive ischemia) by measuring
PT expression levels of particular genes defined in the specification or
PT by determining the expression profile of a gene group comprising these
PT genes -
XX
PS Claim 2; Page 684-685; 2690pp; English.
XX
CC The present invention describes a method for examining ischaemic
CC conditions, comprising measuring the expression levels of particular
CC genes (I) in a test sample or determining the expression profile of a
CC gene group in the sample comprising genes selected from (I). The method
CC is useful for examining the ischaemic condition (e.g. compressive
CC ischaemia, occlusive ischaemia or vasospastic ischaemia) by measuring
CC expression levels of particular genes (ABI99202 to ABI99912, encoding
CC the protein sequences in ABB57020 to ABB57374) or by determining the
CC expression profile of a gene group comprising these genes. The
CC expression levels or expression profiles produced by these genes are
CC used as an indicator when screening for ischaemic condition-improving
CC drugs or therapeutics for ischaemic diseases. ABI99913 and ABI99914
CC represent PCR primers for a mouse ischaemic condition related sequence,
CC which are used in the exemplification of the present invention.
XX
SQ Sequence 217 AA;

Query Match 3.1%; Score 8; DB 23; Length 217;
Best Local Similarity 100.0%; Pred. No. 49;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 116 GAFLIRES 123
||||||||
Db 81 GAFLIRES 88

RESULT 37
ABG06869
ID ABG06869 standard; Protein; 242 AA.
XX
AC ABG06869;
XX
DT 13-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #6860.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS71056.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 37228; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 242 AA;

Query Match 3.1%; Score 8; DB 22; Length 242;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 220 LDSSLLFS 227
||||||||
Db 168 LDSSLLFS 175

RESULT 38
ABB66027
ID ABB66027 standard; Protein; 258 AA.
XX
AC ABB66027;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 24873.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX

PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL10130.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Disclosure; SEQ ID NO 24873; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 258 AA;

Query Match 3.1%; Score 8; DB 22; Length 258;
Best Local Similarity 100.0%; Pred. No. 56;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 SPSLSSSV 20
||||||||
Db 219 SPSLSSSV 226

RESULT 39
AAU31072
ID AAU31072 standard; Protein; 315 AA.
XX
AC AAU31072;
XX
DT 18-DEC-2001 (first entry)
XX
DE Novel human secreted protein #1563.
XX
KW Human; vaccination; gene therapy; nutritional supplement;
KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;
KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.
XX
OS Homo sapiens.
XX
PN WO200179449-A2.
XX
PD 25-OCT-2001.
XX
PF 16-APR-2001; 2001WO-US08656.
XX
PR 18-APR-2000; 2000US-0552929.
PR 26-JAN-2001; 2001US-0770160.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Drmanac RT;
XX
DR WPI; 2001-611725/70.
XX
PT Nucleic acids encoding a range of human polypeptides, useful in genetic
PT vaccination, testing and therapy -
XX
PS Claim 20; Page 399; 765pp; English.
XX
CC The invention relates to novel human secreted polypeptides. The
CC polypeptides and antibodies to the polypeptides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of polypeptide. The polypeptides are also useful for
CC identifying agents (agonists and antagonists) that bind to them. Cells
CC expressing the proteins are useful for identifying a therapeutic agent
CC for use in treatment of a pathology related to aberrant expression or
CC physiological interactions of the polypeptide. Vectors comprising
CC the nucleic acids encoding the polypeptides and cells genetically
CC engineered to express them are also useful for producing the proteins.
CC The proteins are useful in genetic vaccination, testing and
CC therapy, and can be used as nutritional supplements. They may be used to
CC increase stem cell proliferation; to regulate haematopoiesis; and in
CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;
CC immune suppression and/or stimulation; as anti-inflammatory agents; and
CC in treatment of leukaemias. AAU29510-AAU33304 represent the amino acid
CC sequences of novel human secreted proteins of the invention.
XX
SQ Sequence 315 AA;

Query Match 3.1%; Score 8; DB 22; Length 315;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 159 YISPRLTF 166
||||||||
Db 182 YISPRLTF 189

RESULT 40
AAR26061
ID AAR26061 standard; Protein; 317 AA.
XX
AC AAR26061;
XX
DT 02-FEB-1993 (first entry)
XX
DE Growth Factor Receptor Bound protein GRB-2 partial sequence.
XX
KW Tyrosine phophorylation; epidermal growth factor receptor; EGFR;
KW src homology domain; SH2; SH3.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Domain 30
FT /note= "start of SH2 domain"
FT Domain 133
FT /note= "start of SH3 domain"
FT Misc-difference 183
FT /note= "corresponds to CNG codon,
FT where N is unknown"
FT Misc-difference 184
FT /note= "corresponds to TGA codon"
FT Misc-difference 196
FT /note= "corresponds to TAA codon"
FT Misc-difference 199
FT /note= "corresponds to TGA codon"
FT Misc-difference 215
FT /note= "corresponds to TGA codon"
FT Misc-difference 231
FT /note= "corresponds to TGA codon"
FT Misc-difference 202
FT /note= "corresponds to TAA codon"
FT Misc-difference 299
FT /note= "corresponds to TGA codon"
FT Misc-difference 301
FT /note= "corresponds to TAA codon"
FT Misc-difference 302
FT /note= "corresponds to TAA codon"
FT Misc-difference 315
FT /note= "corresponds to TAG codon"
XX
PN WO9213001-A.
XX
PD 06-AUG-1992.

XX
PF 17-JAN-1992; 92WO-US00434.
XX
PR 18-JAN-1991; 91US-0643237.
XX
PA (UYNY) UNIV NEW YORK STATE.
XX
PI Margolis BL, Schlessinger J, Skolnik EY;
XX
DR WPI; 1992-284605/34.
DR N-PSDB; AAQ27255.
XX
PT Probe from tyrosine-phosphorylated portion of receptor tyrosine
PT kinase - used for detection of proteins capable of binding to
PT receptors, useful for e.g. identifying susceptibility to cancer
PT and diabetes
XX
PS Claim 18; Fig 16; 86pp; English.
XX
CC The GRB-2 partial coding sequence was isolated from human brain stem
CC lambda gt11 expression library by screening with tyrosine
CC phosphorylated C-terminal tail of the EGF Receptor. The amino acid
CC sequence deduced from the nucleotide sequence (the "ORF" includes
CC several nonsense codons !) contains unique SH2 and SH3 domains.
CC See also AAQ27254.
XX
SQ Sequence 317 AA;

Query Match 3.1%; Score 8; DB 13; Length 317;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 116 GAFLIRES 123
||||||||
Db 51 GAFLIRES 58

RESULT 41
AAB48967
ID AAB48967 standard; Protein; 402 AA.
XX
AC AAB48967;
XX
DT 27-MAR-2001 (first entry)
XX
DE Human PI3 kinase p55 gamma regulatory subunit.
XX
KW Human phosphatidylinositol 3-kinase p55 gamma regulatory subunit;
KW PI3 kinase p55 gamma; hp55-gamma; p55-gamma; PIK3R3; p55PIK;
KW signal transduction; downstream effector; receptor tyrosine kinase;
KW insulin receptor; IR; insulin-like growth factor receptor; IGFR;
KW cell growth; differentiation; apoptosis; developmental regulation;
KW alternative splicing; tumour formation; cancer; inflammation;
KW infection; expression inhibition; antisense therapy.
XX
OS Homo sapiens.
XX
PN US6165790-A.
XX
PD 26-DEC-2000.
XX
PF 03-NOV-1999; 99US-0433694.
XX
PR 03-NOV-1999; 99US-0433694.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Borchers AH, Cowsert LM, Ward DT;
XX
DR WPI; 2001-101697/11.
DR N-PSDB; AAC92820.
XX
PT Novel antisense compound targeted to human PI3 kinase p55 gamma
PT specifically hybridizes with and inhibits the expression of human PI3
PT kinase p55 gamma, useful for modulating the expression of PI3 kinase
PT p55 gamma in cells -
XX
PS Example 16; Column 45-48; 39pp; English.
XX
CC This sequence represents the human phosphatidylinositol 3-kinase
CC p55 gamma regulatory subunit (PI3 kinase p55 gamma). PI3 kinase
CC p55 gamma (also known as hp55-gamma, p55-gamma, PIK3R3 and p55PIK) is
CC one of several PI3 kinase regulatory subunits that may associate with
CC the PI3 kinase catalytic subunit to form a heterodimeric PI3 kinase
CC holoenzyme. PI3 kinases act as downstream effectors of receptor tyrosine
CC kinases such as growth factor and hormone receptors and oncogene
CC products, and are found in association with the cytoplasmic domains of
CC such receptors. PI3 kinase p55 gamma is able to interact with both the
CC insulin receptor (IR) and the insulin-like growth factor receptor
CC (IGFR), which play important roles in growth, differentiation and
CC apoptosis. PI3 kinase p55 gamma is thought to be developmentally
CC regulated, as four distinct mRNA species are found in adult tissues,
CC while only the larger mRNA is expressed in foetal tissues. The invention
CC relates to antisense oligonucleotides targetted to the PI3 kinase p55
CC gene, which inhibit its expression. A series of oligonucleotides
CC (AAC92827-C92906) were designed to target different regions of human PI3
CC kinase p55 mRNA species, and were analysed for their effect on PI3 kinase
CC p55 mRNA levels by quantitative real-time PCR. The oligonucleotides of
CC the invention are useful for diagnosis, prevention and treatment of
CC conditions associated with PI3 kinase p55 expression, such as tumour
CC formation, inflammation and certain infections, and allow expression
CC level modulation of the alternatively spliced forms of PI3 kinase p55.
XX
SQ Sequence 402 AA;

Query Match 3.1%; Score 8; DB 22; Length 402;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 116 GAFLIRES 123
||||||||
Db 319 GAFLIRES 326

RESULT 42
AAR90571
ID AAR90571 standard; Protein; 454 AA.
XX
AC AAR90571;
XX
DT 09-APR-1996 (first entry)
XX
DE pp60PIK.
XX
KW pp60PIK; 3'-phosphatidyl-inositol kinase; insulin signaling;
KW diabetes; tyrosine kinase.
XX
OS Mus musculus.
XX
FH Key Location/Qualifiers
FT Domain 65..163
FT /label= SH2_domain
FT Domain 358..452
FT /label= SH2_domain
XX
PN WO9534201-A1.
XX
PD 21-DEC-1995.
XX
PF 08-JUN-1995; 95WO-US07312.
XX
PR 10-JUN-1994; 94US-0259264.
XX
PA (JOSL-) JOSLIN DIABETES CENT INC.
XX
PI White MF;

XX
DR WPI; 1996-049325/05.
DR N-PSDB; AAT12235.
XX
PT pp60PIK peptide and transgenic animals contg. a pp60PIK transgene -
PT useful to treat diseases caused by an abnormality in pp60PIK
PT metabolism, e.g. type II diabetes, and as systems to evaluate or
PT screen such treatments
XX
PS Claim 1; Page 29-31; 60pp; English.
XX
CC pp60PIK (AAR90571) is a protein which mediates insulin regulation of
CC 3'-phosphatidyl-inositol kinase. Recombinant pp60PIK can be obtd.
CC by expression of encoding cDNA (AAT12235) in host cells. The pp60PIK
CC is used to treat diseases caused by abnormality in pp60PIK
CC metabolism, e.g. type II diabetes, or diseases caused by unwanted
CC tyrosine kinase activity or abnormal cell proliferation.
XX
SQ Sequence 454 AA;

Query Match 3.1%; Score 8; DB 17; Length 454;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 116 GAFLIRES 123
||||||||
Db 371 GAFLIRES 378

RESULT 43
AAB99332
ID AAB99332 standard; Protein; 505 AA.
XX
AC AAB99332;
XX
DT 23-AUG-2001 (first entry)
XX
DE Human tyrosine kinase Hck protein sequence SEQ ID NO:11.
XX
KW Human; tyrosine kinase Hck binding protein; tyrosine kinase; Hck;
KW tumour lethal factor; tumour necrosis factor alpha; apoptosis; HSB-1;
KW Hck signal transduction; human immunodeficiency virus; HIV infection;
KW anticancer.
XX
OS Homo sapiens.
XX
PN WO200132869-A1.
XX
PD 10-MAY-2001.
XX
PF 26-OCT-2000; 2000WO-JP07500.
XX
PR 29-OCT-1999; 99JP-0309957.
XX
PA (SSSE) SSP CO LTD.
XX
PI Taniyama T, Narita T;
XX
DR WPI; 2001-316440/33.
XX
PT New proteins which bind to human tyrosine kinase Hck for promotion of
PT apoptosis and for the elucidation of the mechanism of Hck signal
PT transduction -
XX
PS Example 1; Page 33-35; 45pp; Japanese.
XX
CC The present invention describes a protein, designated HSB-1, which binds
CC to human tyrosine kinase Hck. Also described are: (1) nucleic acids
CC encoding the protein and its derivatives; (2) recombinant vectors
CC containing the nucleic acids; and (3) host cells transformed by the
CC vectors and expressing the protein. HSB-1 has cytostatic activity, binds
CC tyrosine kinase, enhances tumour necrosis factor alpha and promotes
CC apoptosis. HSB-1 proteins are used for the elucidation of the mechanism
CC of Hck signal transduction and of the role of Hck in human
CC immunodeficiency virus (HIV) infection. They can be used for the
CC treatment of infections and other diseases with which Hck is associated.
CC They promote the anticancer activity of tumour necrosis factor alpha.
CC The present sequence represents the human tyrosine kinase Hck protein,
CC which is used in an example from the present invention.
XX
SQ Sequence 505 AA;

Query Match 3.1%; Score 8; DB 22; Length 505;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 128 GSYSLSVR 135
||||||||
Db 157 GSYSLSVR 164

RESULT 44
AAG41930
ID AAG41930 standard; Protein; 767 AA.
XX
AC AAG41930;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 52229.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.

PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.

PR 29-OCT-1999; 99US-0162142.

Query Match 3.1%; Score 8; DB 21; Length 767;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy      51 LSLRLGEP 58
           ||||||||
Db      22 LSLRLGEP 29
```

RESULT 45
AAG41929
ID AAG41929 standard; Protein; 822 AA.
XX
AC AAG41929;
XX
DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 52228.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.

PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 3.1%; Score 8; DB 21; Length 822;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 LSLRLGEP 58
||||||||
Db 77 LSLRLGEP 84

RESULT 46
ABG25791
ID ABG25791 standard; Protein; 3048 AA.
XX
AC ABG25791;
XX
DT 18-FEB-2002 (first entry)
XX
DE Novel human diagnostic protein #25782.
XX
KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200175067-A2.
XX
PD 11-OCT-2001.
XX
PF 30-MAR-2001; 2001WO-US08631.
XX
PR 31-MAR-2000; 2000US-0540217.
PR 23-AUG-2000; 2000US-0649167.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Drmanac RT, Liu C, Tang YT;
XX
DR WPI; 2001-639362/73.
DR N-PSDB; AAS89978.
XX
PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations
PT responsible for genetic disorders or other traits and to assess
PT biodiversity -
XX
PS Claim 20; SEQ ID No 56150; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 3048 AA;

Query Match 3.1%; Score 8; DB 22; Length 3048;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 116 GAFLIRES 123
||||||||
Db 2585 GAFLIRES 2592

```
RESULT 47
AAB66758
ID   AAB66758 standard; peptide; 10 AA.
XX
AC   AAB66758;
XX
DT   10-APR-2001  (first entry)
XX
DE   Beta6 cytoplasmic tail domain biotinylated peptide #3.
XX
KW   MAP; mitogen activated protein; integrin; beta6; cancer; colon.
XX
OS   Homo sapiens.
XX
PN   WO200100677-A1.
XX
PD   04-JAN-2001.
XX
PF   28-JUN-2000; 2000WO-AU00729.
XX
PR   28-JUN-1999;   99AU-0001248.
PR   06-JUN-2000; 2000AU-0008003.
XX
PA   (UYNE-) UNIV NEWCASTLE RES ASSOC LTD.
XX
PI   Agrez MV;
XX
DR   WPI; 2001-071476/08.
XX
PT   Polypeptide capable of binding with a binding site on a MAP (mitogen
PT   activated protein) kinase which binds with a binding domain of an
PT   integrin for the MAP kinase, useful for the treatment of cancer,
PT   particularly colon cancer -
XX
PS   Example 3; Page 87; 160pp; English.
XX
CC   The present invention relates to peptides capable of binding
CC   a site on a MAP (mitogen activated protein) kinase which binds
CC   a binding domain of an integrin for the MAP kinase. The peptide
CC   is other than a full length integrin subunit.
CC   The peptides, related nucleic acids, and agents are useful for the
CC   treatment of cancer, particularly colon cancer.
XX
SQ   Sequence   10 AA;

  Query Match             2.7%;  Score 7;  DB 22;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 29;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      29 EAERSKA 35
           |||||||
Db       3 EAERSKA 9


RESULT 48
ABG34896
ID   ABG34896 standard; Peptide; 14 AA.
XX
AC   ABG34896;
XX
DT   15-JUL-2002  (first entry)
XX
DE   Human G-protein coupled receptor, cAMP/cGMP phosphorylation site #3.
XX
KW   Human; G-protein coupled receptor; HGPRBMY6; small intestine; colon;
KW   testis; cancer; receptor.
XX
OS   Homo sapiens.
XX
PN   WO200226987-A2.
XX
PD   04-APR-2002.
XX
PF   26-SEP-2001; 2001WO-US30614.
XX
PR   27-SEP-2000; 2000US-235602P.
PR   19-JUL-2001; 2001US-306604P.
PR   28-AUG-2001; 2001US-315412P.
XX
PA   (BRIM ) BRISTOL-MYERS SQUIBB CO.
XX
PI   Feder JN,  Mintier G,  Ramanathan CS,  Hawken DR,  Cacace A,  Barber L;
PI   Kornacker MG;
XX
DR   WPI; 2002-383273/41.
XX
PT   Novel isolated polynucleotide encoding a human G protein coupled
PT   receptor, both useful for treating condition of the small intestine,
PT   colon, or testis -
XX
PS   Disclosure; Page 53; 174pp; English.
XX
CC   The invention relates to an isolated polynucleotide encoding a human G-
CC   protein coupled receptor, HGPRBMY6. The polypeptide and polynucleotide
CC   are used to treat, and diagnose a disease, disorder or condition
CC   associated with the small intestine, colon, or testis, particularly
CC   cancer. ABG34861-ABG34924 represent human G-protein coupled receptor
CC   amino acid sequences and related sequences of the invention.
XX
SQ   Sequence   14 AA;

  Query Match             2.7%;  Score 7;  DB 23;  Length 14;
  Best Local Similarity   100.0%;  Pred. No. 39;
  Matches    7;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       7 RRKSLPS 13
           |||||||
Db       6 RRKSLPS 12


RESULT 49
AAB66752
ID   AAB66752 standard; peptide; 22 AA.
XX
AC   AAB66752;
XX
DT   10-APR-2001  (first entry)
XX
DE   Beta6 cytoplasmic tail domain fragment #1.
XX
KW   MAP; mitogen activated protein; integrin; beta6; cancer; colon.
XX
OS   Homo sapiens.
XX
PN   WO200100677-A1.
XX
PD   04-JAN-2001.
XX
PF   28-JUN-2000; 2000WO-AU00729.
XX
PR   28-JUN-1999;   99AU-0001248.
PR   06-JUN-2000; 2000AU-0008003.
XX
PA   (UYNE-) UNIV NEWCASTLE RES ASSOC LTD.
XX
PI   Agrez MV;
XX
DR   WPI; 2001-071476/08.
XX
PT   Polypeptide capable of binding with a binding site on a MAP (mitogen
PT   activated protein) kinase which binds with a binding domain of an
PT   integrin for the MAP kinase, useful for the treatment of cancer,
PT   particularly colon cancer -
XX
```

PS Example 3; Page 84; 160pp; English.
XX
CC The present invention relates to peptides capable of binding
CC a site on a MAP (mitogen activated protein) kinase which binds
CC a binding domain of an integrin for the MAP kinase. The peptide
CC is other than a full length integrin subunit.
CC The peptides, related nucleic acids, and agents are useful for the
CC treatment of cancer, particularly colon cancer.
XX
SQ Sequence 22 AA;

Query Match 2.7%; Score 7; DB 22; Length 22;
Best Local Similarity 100.0%; Pred. No. 56;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 29 EAERSKA 35
|||||||
Db 10 EAERSKA 16

RESULT 50
AAY22150
ID AAY22150 standard; Protein; 24 AA.
XX
AC AAY22150;
XX
DT 08-SEP-1999 (first entry)
XX
DE Peptide used for FHV chimeric particle construction.
XX
KW Nodavirus capsid protein; chimeric protein; anti-parallel beta barrel;
KW immune response; chimeric virus-like particle; gene-delivery vector;
KW hepatitis B infection; vaccine; vesicular stomatitis viral infection;
KW respiratory syncytial virus; malaria; Flock House virus; FHV.
XX
OS Synthetic.
XX
PN WO9929723-A1.
XX
PD 17-JUN-1999.
XX
PF 07-DEC-1998; 98WO-US25922.
XX
PR 08-DEC-1997; 97US-0986659.
XX
PA (PENT-) PENTAMER PHARM.
PA (SCRI) SCRIPPS RES INST.
XX
PI Hall SG;
XX
DR WPI; 1999-385574/32.
XX
PT Recombinant chimeric nodavirus particles
XX
PS Disclosure; Page 62; 69pp; English.
XX
CC This sequence represents a peptide used in the construction of a
CC flock house virus (FHV) chimeric particle.
CC The invention relates to a chimeric protein comprising a nodavirus capsid
CC protein free from deletions, having a core structure constituted by
CC anti-parallel beta barrels, and a heterologous peptide segment situated
CC between a pair of strands of one of the beta barrels. The chimeric
CC protein is used to induce an immune response in an animal. The chimeric
CC proteins can be assembled to form chimeric virus-like particles that are
CC useful in therapeutic applications, such as vaccines and gene-delivery
CC vectors, and in diagnostic applications, such as kits for the testing of
CC body tissue or fluid samples. The chimeric virus-like particles mimic
CC infectious viruses and parasites and are useful for treating hepatitis B
CC infection, vesicular stomatitis viral infection, bovine and human
CC respiratory syncytial virus, as well as malaria. Flock House virus (FHV)
CC is a non-pathogenic nodavirus that can be used to genetically engineer
CC virus-like particles carrying antigenic peptides on their surface. The
CC FHV capsid protein has a remarkable functional versatility. A region of
CC the capsid protein is amenable to insertion of heterologous peptide
CC segments without affecting assembly of the viral coat or capsid.
XX
SQ Sequence 24 AA;

Query Match 2.7%; Score 7; DB 20; Length 24;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 43 FPAGGPA 49
|||||||
Db 15 FPAGGPA 21

Search completed: March 24, 2003, 16:07:01
Job time : 49 secs